Skip to main content
    D

    DexCom Inc (DXCM)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $81.61
    -1.72 (-2.06%)

    Market Cap: $31.08B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    DexCom Inc (DXCM) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    DexCom (DXCM) trades at 30.6x trailing earnings and 6.0x sales. Its P/E of 30.6x is below its 5-year median of 67.5x. Its forward P/E is 26.9x. The median P/E across 8 similar companies is 19.4x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 13.8% higher over the next year. Its free cash flow yield is 3.6%.

    MultipleValue
    P/E (trailing)30.6x
    Forward P/E26.9x
    Price to sales6.0x
    Price to book12.1x
    EV/EBITDA20.1x
    Price to FCF27.8x
    EV/FCF28.1x
    PEG1.3
    FCF yield3.6%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 47.4% below 11.4x and its P/B is 37.9% below 19.5x.

    MultipleCurrent5-year median10-year median
    P/E30.6x67.5xN/A
    P/S6.0x8.4x11.4x
    P/B12.1x15.7x19.5x
    Medians of month-end values through Oct 2026: 52 to 60 months (5-year) and 98 to 115 months (10-year).

    Valuation History

    Over the 8 of the 10 year ends shown that have a P/E, its P/E ranged from 31.8x in 2025 to 374.4x in 2018. 2025 was the lowest of those years.

    Year endPriceP/EP/SP/B
    2025$66.3731.8x5.6x9.6x
    2024$77.7747.1x7.7x15.0x
    2023$124.0982.2x13.5x24.9x
    2022$113.24130.2x18.7x22.6x
    2021$134.24203.4x27.4x24.3x
    2020$92.43118.5x23.2x78.9x
    2019$54.69118.9xN/A23.0x
    2018$29.95374.4x12.6x21.9x
    2017$14.35N/A6.9x11.9x
    2016$14.93N/A8.7x17.8x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About DXCM

    What is DXCM's forward P/E ratio?

    DexCom has a forward P/E ratio of 26.9x.

    Is DXCM stock overvalued?

    GNG's valuation label for DXCM is Undervalued. Its P/E of 30.6x compares with a median of 19.4x across 8 similar companies.

    What is DXCM's price to sales ratio?

    DexCom has a price to sales ratio of 6.0x.

    What is DexCom's average P/E ratio over 5 years?

    DexCom's median P/E over the last 5 years is 67.5x, from 60 month-end values through Oct 2026.

    What is DXCM's PEG ratio?

    DexCom has a PEG ratio of 1.3.